Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Topical rhGM-CSF on Venous Leg Ulcers
NCT04823962Phase 2Unknown
- Sponsor
- Reponex Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in venous leg ulcer (VLU), sponsored by Reponex Pharmaceuticals. Status: unknown.
02
Drugs
sargramostim
03
Conditions
venous leg ulcer (VLU)
Beyond the preview
Go deeper on NCT04823962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04823962.